SALT
LAKE CITY, Aug. 18, 2023 /PRNewswire/ --
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a
molecular diagnostics company with a unique, patented platform for
the development of molecular diagnostic tests, announced today that
it will be sponsoring, presenting and hosting a booth at the
15th Annual Next Generation Dx Summit, held virtually
and in-person in Washington, D.C.
on August 21-23, 2023.
The Next Generation Dx Summit offers a valuable window into how
point-of-care, decentralized testing, infectious
disease, liquid biopsy and companion diagnostics are changing the
standard of care. This year's summit includes four streams:
Point-of-Care and Infectious Disease, Companion Diagnostics and
Reimbursement, Liquid Biopsy and Early Detection, and
Decentralized Testing.
On Monday, August 21, at
12:15 PM ET, Company CEO Dwight Egan will be presenting on the Company's
forthcoming Co-Dx PCR Home™ platform, which is subject to FDA
review and not currently for sale, in a luncheon presentation
titled "Co-Dx PCR Home: Transforming Infectious Disease Diagnosis
Worldwide."
In-person visitors are invited to visit the Company at Booth
#204. To learn more about the summit, including in-person and
virtual registration details, please visit
https://www.nextgenerationdx.com.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR Home™ platform and to locate genetic
markers for use in applications other than infectious disease.
View original
content:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-present-at-15th-next-generation-dx-summit-in-washington-dc-301904317.html
SOURCE Co-Diagnostics